Clinical Trials
110 trialsTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
TTBF
University of California, San Francisco
OvAR-Y
Washington University School of Medicine
Brodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
iCaRe2
University of Nebraska
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Stanford University
ART-Hypo
Centre hospitalier de l'Université de Montréal (CHUM)
MOMENTUM
UMC Utrecht
Improving Care for Rural Patients With Solid Tumors
University of Colorado, Denver
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
City of Hope Medical Center
SCORE
Natera, Inc.
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
VARTUTRACE
Var2 Pharmaceuticals
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
AYAConnect
UNC Lineberger Comprehensive Cancer Center
DENALI-1
A2 Biotherapeutics Inc.
FIDURA
Sahlgrenska University Hospital
Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers
City of Hope Medical Center
ORACLE
Guardant Health, Inc.
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
A Clinical Evaluation of AI Solutions Developed in the CHAIMELEON Project for Cancer: Prostate, Lung, Breast, Colon and Rectum
Instituto de Investigacion Sanitaria La Fe
HERO
Rutgers, The State University of New Jersey
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
Stanford University
PRECANU
Aalborg University Hospital
Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients
Mansoura University
ROOT
Taproot Health
COST-FIN
Northwestern University
SPIRIT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
RADIANT
DxTerity Diagnostics
GI Organ Tracking Via Balloon Applicators
Washington University School of Medicine
A Randomized Controlled Trial of the Safety and Efficacy of Robotic Telesurgery Versus Laparoscopic Surgery
Sun Yat-sen University
VAMIS
The Griffin Institute
MIFADORESOL
Institut de cancérologie Strasbourg Europe
HETERERO
Charite University, Berlin, Germany
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Corvus Pharmaceuticals, Inc.
Ultrasound Spectroscopy as Early Indicators of Radiation Treatment Response in Prostate, Rectum and Head & Neck Cancers
Sunnybrook Health Sciences Centre
ART-02
Charite University, Berlin, Germany
ASPIRE
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study
M.D. Anderson Cancer Center
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Klus Pharma Inc.
Study of Symptoms Caused by Cancer and Cancer Therapy in Patients With Invasive Breast, Lung, Prostate, or Colorectal Cancer
Eastern Cooperative Oncology Group
Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
Eastern Cooperative Oncology Group
SPACE2
Weprom
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
MacroGenics
Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients
RenJi Hospital
Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking
Wake Forest University Health Sciences
Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites
Jerome Canady Research Institute for Advanced Biological & Technological Sciences
ONCODAGE
Institut Bergonié
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
Abramson Cancer Center at Penn Medicine